EGFR and acute myeloid leukemia: Of note, oncogenic roles for METTL3 and METTL14 have been described in several human cancers including acute myeloid leukemia (AML), lung and liver cancer in which they increase the expression of oncogenes, e.g., MYC, SNAI1, and EGFR, or enhance the degradation of tumor suppressors, e.g., suppressor of cytokine signaling 2 (SOCS2) to drive tumor growth signaling.